- Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC):
- PO 24mg (two 10mg capsules and one 4mg capsule) OD
- PO 24mg (two 10mg capsules and one 4mg capsule) OD
- Advanced renal cell carcinoma:
- Combination with pembrolizumab first-line treatment:
- PO 20mg OD plus IV pembrolizumab 200mg every 3 weeks OR 400mg every 6 weeks
- Give for up to 2 years with pembrolizumab, then may give as monotherapy
- Combination with pembrolizumab first-line treatment:
-
- Combination with everolimus in prior antiangiogenic treatment:
- PO 18mg (one 10mg capsule and two 4mg capsules) OD plus PO everolimus 5mg OD
- PO 18mg (one 10mg capsule and two 4mg capsules) OD plus PO everolimus 5mg OD
- Combination with everolimus in prior antiangiogenic treatment:
- First-line treatment in unresectable hepatocellular carcinoma (HCC):
- < 60kg: PO 8mg OD
- >60kg: PO 12mg OD
- Advanced endometrial carcinoma in patients with disease progression following prior systemic therapy and are not candidates for curative surgery or radiation:
- PO 20mg OD plus IV pembrolizumab 200mg every 3 weeks
- Capsule:
- 4mg
- 10mg
- Capsule should not be opened but may be dissolved whole in water or apple juice
VEGF Inhibitor anticancer
It inhibits multiple tyrosine kinases including VEGF, resulting in decreased angiogenesis, tumor growth and cancer progression
- Hypertension
- Fatigue
- Diarrhea
- Arthralgia
- Myalgia
- Decreased appetite
- Decreased weight
- Abdominal pain
- Nausea
- Proteinuria
- Hand-foot syndrome
- Dysphonia
- Vomiting
- Stomatitis
- Constipation
- Headache
- Rash
- Peripheral edema
- Hemorrhage
- Hypothyroidism
- Ascites
- Fever
- Renal impairment
- Oral pain
- Cough
- Dysgeusia
- Xerostomia
- Dizziness
- Dyspepsia
- Alopecia
- Epistaxis
- Insomnia
- UTI
- Hypercalcemia
- Dental infection
- Hypotension
- Dehydration
- Qt prolongation
- Arterial thromboembolism
- Cardiac dysfunction
- Hyperkeratosis
- GI perforation
- Fistula
- Increased GGT
- Hyponatremia
- Increased ALT/AST
- Hypersensitivity to components/class
- Arterial thromboembolism within 6 months
- Uncontrolled hypertension
- Uncorrected electrolyte abnormalities
- GI perforation
- Grade 3-4 fistula
- Unhealed surgical wound
- Major surgery within prior 2 weeks
- Avoid treatment for at least 1 week before elective surgery or invasive dental procedure
- Avoid breastfeeding during treatent and for at least 1 week after discontinuation
- Cidofovir
- Pimozide
- Thioridazine
- Elagolix
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Lenvanix | 4mg | Capsule | 30’s | Beacon Medicare Limited | Generics Africa |
| Lenvanix | 10mg | Capsule | 30’s | Beacon Medicare Limited | Generics Africa |